Iradimed shareholders back board, auditor and pay policies
TipRanks (Wed, 24-Jun 10:47 AM ET)
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Wed, 20-May 8:30 AM ET)
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Globe Newswire (Fri, 1-May 8:30 AM ET)
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
Globe Newswire (Mon, 27-Apr 8:30 AM ET)
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Fri, 10-Apr 3:14 PM ET)
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Iradimed trades on the NASDAQ stock market under the symbol IRMD.
As of June 29, 2026, IRMD stock price declined to $93.74 with 43,368 million shares trading.
IRMD has a beta of -0.26, meaning it tends to be less sensitive to market movements. IRMD has a correlation of 0.01 to the broad based SPY ETF.
IRMD has a market cap of $1.20 billion. This is considered a Small Cap stock.
Last quarter Iradimed reported $22 million in Revenue and $.49 earnings per share. This beat revenue expectation by $601,000 and exceeded earnings estimates by $.05.
In the last 3 years, IRMD traded as high as $107.90 and as low as $36.12.
The top ETF exchange traded funds that IRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, FYC.
IRMD has outperformed the market in the last year with a price return of +56.4% while the SPY ETF gained +21.8%. However, in the short term, IRMD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -4.9% vs +14.7% return in SPY. But in the last 2 weeks, IRMD shares have fared better than the market returning +0.1% compared to SPY -0.2%.
IRMD support price is $91.65 and resistance is $96.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRMD shares will trade within this expected range on the day.